- Could Asthma Harm a Child’s Memory Skills?
- Report Finds Big Disparities in Americans’ Well-Being by Region
- Weight Loss Meds Help Stroke Survivors Prevent Stroke Recurrence, Death
- Diabetes & Kidney Trouble Can Bring Heart Disease Decades Earlier
- Hourglass-Shaped Stent Might Ease Tough-to-Treat Angina
- Bystanders More Readily Perform CPR If 911 Operator Instructs
- How ADHD May Influence a Child’s Weight
- Have an Implanted Defibrillator? Triple-Digit Heatwaves Could Pose Danger
- Obesity-Linked Heart Deaths Nearly Tripled in U.S. Over Past Two Decades
- Unexplained Weight Loss and What It Can Mean for Your Health
Brain-Imaging Drug Approved for Alzheimer’s Detection
FRIDAY, Oct. 25Vizamyl (flutemetamol F 18 injection) has been approved by the U.S. Food and Drug Administration for use with positron emission tomography (PET) imaging of the brain to screen adults for signs of Alzheimer’s disease and other forms of dementia.
Dementia — characterized by deteriorating memory, judgment, language and motor skills — has been associated with brain accumulation of a protein called beta amyloid. Vizamyl, combined with a PET scan, can help doctors detect this protein, the FDA said Friday in a news release.
Vizamel, the second diagnostic drug approved for this purpose, was evaluated in clinical studies of 761 people. The injected drug is not meant to predict whether a person will go on to develop Alzheimer’s or other types of dementia, or to evaluate how people may respond to dementia therapies, the FDA warned.
Potential side effects of the drug include allergic-like reaction, becoming flushed, headache, a rise in blood pressure, nausea and dizziness, the agency said.
Vizamyl is produced for GE Healthcare by Medi-Physics Inc., based in Arlington Heights, Ill.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.